Palvella Therapeutics (PVLA) Research & Development (2014 - 2026)

Palvella Therapeutics (PVLA) has 13 years of Research & Development data on file, last reported at $9.3 million in Q1 2026.

• On a quarterly basis, Research & Development rose 129.11% year-over-year to $9.3 million in Q1 2026; TTM through Mar 2026 was $28.1 million, a 149.99% increase from a year earlier, with the FY2025 full-year figure at $22.8 million, up 180.22% from the prior year.
• Research & Development for Q1 2026 stood at $9.3 million, up from $7.1 million in the prior quarter.
• Over the last five years, Research & Development for PVLA reached as high as $14.3 million in Q2 2023 and fell as low as -$28.6 million in Q4 2023.
• Historically, Research & Development has averaged $6.0 million across 5 years, with a median of $7.1 million in 2025.
• Across the five-year window, Research & Development sank 313.41% in 2023 and surged 314.02% in 2025, its largest moves.
• Year by year, Research & Development stood at $13.4 million in 2022, then sank by 313.41% to -$28.6 million in 2023, then soared by 108.91% to $2.5 million in 2024, then surged by 180.02% to $7.1 million in 2025, then soared by 31.08% to $9.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $9.3 million in Q1 2026, $7.1 million in Q4 2025, and $6.5 million in Q3 2025.